Danielle Elsberry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danielle Elsberry has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Kittai
Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
11 shared publications - Ashley Krull
The Ohio State University, Columbus, Ohio, USA
11 shared publications - Dean Anthony Lee
Nationwide Children’s Hospital 12 Division of Hematology/Oncology/BMT Columbus, Ohio
11 shared publications - Dina Schneider
Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD
11 shared publications - Elizabeth George
Nationwide Children’s Hospital 11 Office of Research Regulatory Affairs Columbus, Ohio
11 shared publications - Evandro Dantas Bezerra
24Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH
11 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 2. Trispecific CAR T Cell Persistence by gag gene PCR (single dose infusion versus split dose infusion).
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 2. Trispecific CAR T Cell Persistence by gag gene PCR (single dose infusion versus split dose infusion).
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 4. Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in post-CAR T infusion PBMCs at Day 7.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 4. Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in post-CAR T infusion PBMCs at Day 7.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 1. Trial Schema.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 1. Trial Schema.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 2. Toxicity and other clinical outcomes.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 2. Toxicity and other clinical outcomes.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 6. Trispecific CAR + T cell Gating Strategy for spectral flow cytometry.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 6. Trispecific CAR + T cell Gating Strategy for spectral flow cytometry.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 3. Statistical Analysis (Area Under the Curve) Trispecific CAR T Cell Persistence by PCR Data.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 3. Statistical Analysis (Area Under the Curve) Trispecific CAR T Cell Persistence by PCR Data.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 5: Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in Post-CAR T PBMCs at Day 14.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 5: Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in Post-CAR T PBMCs at Day 14.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 1. Representativeness of Study Participants.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 3. 40 color spectral flow cytometry CAR T cell immunophenotyping panel.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 3. 40 color spectral flow cytometry CAR T cell immunophenotyping panel.